** Shares of the New York-based drug developer IN8bio INAB.O rises 17.5% to 31 cents
** Co says early-stage trial showed its experimental cancer therapy helped all 9 patients with a type of blood cancer remain in complete remission
** Co's therapy, INB-100, also helped increase survival rates of patients compared to historical data and the time they lived without their cancer worsening
** INAB was testing its therapy to treat acute myeloid leukemia, a cancer of the blood and bone marrow
** INB-100 uses gamma-delta T cells, that are rarely found in secondary lymphoid organs and play a role in helping control cancer activity, to target the disease
** Patients treated with INB-100 also showed prolonged and durable decrease in symptoms of their cancer beyond one year
** In the last 12 months, INAB has fallen 70.27%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。